BLACKSBURG, Va., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will present a company overview at the Cowen and Company 40^th Annual Health Care Conference. The presentation will take place on Monday, March 2, 2020, at 10:30 a.m. EST at the Boston Marriott Copley Place. A live and archived audio webcast of the presentation will be accessible in the Company’s Events & Presentations section at www.landosbiopharma.com.

About Landos Biopharma

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company completed Phase 1 clinical testing in 2018 and initiated global Phase 2 clinical testing of BT-11 for ulcerative colitis (UC) in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which Landos anticipates will advance to Phase 1 clinical testing in 2020. For more information, please visit www.landosbiopharma.com.

Contacts:
Chiara Russo (investors)
Solebury Trout
617-221-9197
crusso@troutgroup.com

Rich Allan (media)
Solebury Trout
646-378-2958
rallan@troutgroup.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.